Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | METAP2 | P50579 | 1/20 | 0.39 |
| ▸ | IDO1 | P14902 | 1/20 | 0.38 |
| ▸ | TDO2 | P48775 | 1/20 | 0.38 |
| ▸ | SPR | P35270 | 3/20 | 0.33 |
| ▸ | CCNE1 | P24864 | 3/20 | 0.33 |
| ▸ | CDK2 | P24941 | 3/20 | 0.33 |
| ▸ | CDK3 | Q00526 | 3/20 | 0.33 |
| ▸ | CDK1 | P06493 | 1/20 | 0.33 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.33 |
| ▸ | NOS1 | P29475 | 1/20 | 0.33 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.33 |
| ▸ | GRK2 | P25098 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20042288 | 0.96 | METAP2 (0.40) | METAP2IDO1TDO2SPRCCNE1 | |
| SCHEMBL20002461 | 0.93 | METAP2 (0.41) | METAP2IDO1TDO2CCNE1CDK2 | |
| SCHEMBL17731744 | 0.89 | METAP2 (0.42) | METAP2IDO1TDO2CCNE1CDK2 | |
| SCHEMBL17738740 | 0.88 | METAP2 (0.43) | METAP2IDO1TDO2NOS1DYRK1A | |
| SCHEMBL20002529 | 0.87 | METAP2 (0.37) | METAP2IDO1TDO2CCNE1CDK2 | |
| SCHEMBL20938995 | 0.84 | METAP2 (0.45) | METAP2IDO1TDO2NOS1DYRK1A | |
| SCHEMBL30602739 | 0.84 | METAP2 (0.45) | METAP2IDO1TDO2NOS1DYRK1A | |
| SCHEMBL20002074 | 0.79 | TDO2 (0.38) | TDO2NOS1 | |
| SCHEMBL17739249 | 0.78 | METAP2 (0.40) | METAP2IDO1TDO2CCNE1CDK2 | |
| SCHEMBL17738671 | 0.78 | METAP2 (0.40) | METAP2IDO1TDO2CCNE1CDK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180099939-A1 | COMPOUNDS AND METHODS FOR IDO AND TDO MODULATION AND INDICATIONS THEREFOR | PLEXXIKON INC. | 2018-04-12 | — | — | US | disclosed |
| US-20180099939-A1 | COMPOUNDS AND METHODS FOR IDO AND TDO MODULATION AND INDICATIONS THEREFOR | PLEXXIKON INC. | 2018-04-12 | — | — | US | disclosed |
| WO-2018057973-A1 | COMPOUNDS AND METHODS FOR IDO AND TDO MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON INC. (US) | 2018-03-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180099939-A1 | COMPOUNDS AND METHODS FOR IDO AND TDO MODULATION AND INDICATIONS THEREFOR | IDO1, TDO2, IDO2 | METAP2 786/4885IDO1 1/4885TDO2 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.